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Studying potential drug interactions involved 
in the regulation of the Diaphanous-related 
formins
Brittany E. Benson and Dr. Bradley J. Wallar
       Student Summer Scholars Program 2008
Diaphanous-related formins 
(DRFs) are a conserved family of 
proteins that are involved in the 
regulation of cellular shape, motility, 
and cell division by regulating the 
structure of the cellular “skeleton” 
(cytoskeleton); any disruption of this 
regulation can result in cell death. 
Normally, the DRFs are kept in an 
inactive state by the intramolecular 
binding of two regions of the protein: 
the Diaphanous Autoregulatory 
Domain (DAD) and Diaphanous 
Inhibitory Domain (DID).  This 
binding can be alleviated by various 
naturally-occurring mechanisms and 
proper regulation of the activity of 
these proteins is vital to cell survival 
because prolonged activation of DRFs 
can result in cell death.  In a recent 
scan of 10,000 chemical compounds, 
two compounds (I and II) were 
identified to bind to the DID region 
and activate DRFs indefinitely 
resulting in the killing of breast and 
colon cancer cells.  In this study, we 
intend to prove that these compounds 
are actually alleviating DID-DAD 
binding (the essential step in DRF 
activation) by directly binding to DID. 
In addition, the specific location on 
DID that binds these compounds must 
be elucidated.  We have hypothesized 
three amino acid residues that 
contribute to the binding of these 
compounds, have generated them 
using site-directed mutagenesis, and 
have evaluated their ability to bind 
the compounds using fluorescence 
anisotropy. Further experiments will 
test how these DID mutations affect 
the ability for these compounds to 
directly bind to DID using isothermal 
titration calorimetry.  By 
characterizing the DID-compound 
bound structure, these studies will 
allow for the design of new 
compounds that could bind more 
tightly to DID, thereby resulting in a 
drug that could efficiently kill cancer 
cells.
Introduction
The Diaphanous-related formins (DRFs) 
are a conserved group of proteins found 
in many species, including yeast, slime 
mold, worms, fruit flies, humans, and 
others (1).  They are responsible for the 
remodeling of the cytoskeleton by 
regulating actin nucleation and 
elongation through the interaction with 
their conserved formin homology 2 
(FH2) domain (1,2).  As a result, they 
are involved in any process that requires 
modification of the cytoskeleton, 
including cell division, cell migration, 
cell shape, and trafficking of cellular 
proteins.
Because these proteins control 
such integral processes in the cell, their 
tight regulation is a necessity for normal 
cellular growth.  Any disruption of the 
DRF regulation results in cellular 
abnormalities, and eventually, apoptosis 
(cellular ‘suicide’).  Normally, the 
Diaphanous-related formins are 
autoregulated by the binding of their N-
terminal Diaphanous-inhibitory Domain 
(DID) to the C-terminal Diaphanous-
autoregulatory Domain (DAD), creating 
a closed, inactive state (3,4) (see Figure 
1).  In this conformation, the FH2 
domain is unexposed and thus unable to 
nucleate actin (3,5).  Naturally occurring 
mechanisms exist that can activate DRFs 
through disrupting this binding and 
creating an open, active state.  These 
signaling proteins, such as Rho 
GTPases, can temporarily bind to 
another domain, the GTPase binding 
domain (GBD), displacing DAD from 
DID and creating the open conformation 
in which the FH2 domain is available to 
nucleate actin and activate other cellular 
processes (3,5,6) (see Figure 2).  
In knowing that any disruption of 
these naturally occurring regulatory 
mechanisms can elicit cell death, our 
collaborators at the Van Andel Research 
Institute initiated a 10,000 compound 
scan to search for compounds that may 
bind to DRFs and specifically disrupt the 
DID-DAD interactions, thereby creating 
a permanent active state.  Using a high-
throughput approach to a fluorescence 
anisotropy assay designed and optimized 
by Dr. Brad Wallar at GVSU, they 
discovered two compounds (I/II) that 
theoretically can bind to DID and 
subsequently have been shown to kill 
breast and colon cancer cells (see Figure 
3).  The goal of our project was to prove 
that those cells died as a result of these 
compounds binding to DID and up-
regulating DRFs by creating a 
permanent open, active state. 
Furthermore, we have planned to 
elucidate the mechanism of this binding. 
In order to explain the binding of 
compounds I/II to DRFs (specifically 
mDia2), we considered a known 
structure of a similar DRF protein, as 
well as predictions based on molecular 
docking studies (computer modeling). 
From these data, we have hypothesized 
three residues (arginine-230, 
isoleucine-276 and glutamine-322) 
within the DID domain contribute to the 
binding of compounds I/II. This project 
was aimed at determining the 
importance of these residues in DID-
DAD binding and for compounds I/II to 
bind to DID, as well as how strongly 
these compounds bind to DID.  In order 
to accomplish this aim, we have made 
mutations of these amino acid residues 
(arginine-230 to a leucine, 
isoleucine-276 to an aspartate and 
glutamine-322 to a leucine).  These 
mutations change the polarity of each 
residue and thus affect its ability to 
hydrogen bond or interact with residues 
of similar chemical properties.  If these 
residues are indeed involved in DID-
DAD or DID-compound binding, then 
these mutations should result in a loss of 
that binding.
Discovering compounds that can 
bind to DID, alleviate DID-DAD 
binding, and subsequently kill cancer 
cells represents an opportunity to create 
a new chemotherapeutic drug.  Many 
current chemotherapeutic drugs, such as 
Paclitaxel (commonly known as Taxol) 
work by targeting the cytoskeleton, 
binding directly to microtubules and 
stabilizing them, preventing their 
depolymerization and leading to mitotic 
arrest (7).  These compounds act 
similarly to Taxol, but instead target the 
proteins that regulate the cytoskeleton 
rather than directly targeting the 
cytoskeleton.  While Taxol has been an 
effective chemotherapeutic treatment, it 
also exhibits side effects and tumor cell 
resistance, and so it is now important to 
identify other compounds that can 
disrupt cytoskeletal function.  
Materials and Methods
 
Mutagenesis and 
Transformation: Plasmid DNA of the 
mutants R230L, Q322L, I276D and wild 
type GST-mDia2 (47-396) were 
obtained using the Quikchange II XL 
mutagenesis kit (Stratagene), and were 
sent to the University of Michigan for 
sequence verification.  For protein 
production, these plasmids were then 
transformed into 50μL of competent 
Rosetta 2 (DE3) cells.  These cells were 
incubated for 30 minutes on ice, heat 
shocked at 42˚C for 30 seconds and then 
incubated on ice for an additional 2 
minutes.  200μL of SOC medium was 
added and the cells were incubated at 
37˚C while gently shaking for 20 
minutes.  Samples were then plated on 
LB-ampicillin (100μg/mL)- 25μg/mL 
chloramphenicol plates and grown up 
overnight at 37˚C.
Expression and Purification of  
Protein: One colony from each plate was 
added to 50mL of LB media inoculated 
with 100μg/mL ampicillin and 25μg/mL 
chloramphenicol, which was gently 
shaken overnight at 37˚C.  These 
cultures were then diluted into 1L LB 
broth and 100μg/mL ampicillin, 
25μg/mL chloramphenicol and shaken at 
37˚C until the OD600 reached 0.6-0.8, 
then incubated at 16˚C for 30 minutes 
and induced with 1mM isopropyl-β-D-
thiogalactopyranoside (IPTG) overnight 
at 16˚C.  Cells were lysed with lysis 
buffer (25mM Tris-Cl, pH 7.5, 100mM 
NaCl and 10mM MgCl2, HALT-Pierce 
Protease Inhibitors, 50U DNase I and 
2mM DTT), sonicated (4 x 15 seconds) 
and centrifuged at 15,000 rpm for 30 
minutes at 4˚C.  Glutathione-agarose 
beads were then added to the supernatant 
(cell-free extract), incubated at 4˚C for 1 
hour then washed 4 x 50mL with a wash 
buffer of 200mL TMN (25mM Tris-Cl, 
pH 7.5, 10mM MgCl2, 100mM NaCl) 
with 0.1g DTT.  Protein was eluted from 
these beads using elution buffer (100mM 
Tris-HCl, pH 8.0, 20mM reduced 
glutathione, and 10mM DTT) and 
concentrated to ~3mL using Amicon 
Biomax 10 kDa cutoff filters, 
centrifuging at 3,000 rpm and 4˚C. 
Aliquots from throughout the 
purification process were run on an 
SDS-PAGE gel to verify the purity of 
the final protein.  Concentration was 
determined by measuring absorbance at 
280 nm and applying the theoretical 
extinction coefficient of 51,490 M-1cm-1. 
Fluorescence Anisotropy:  
Binding studies were completed at 25ºC 
using fluorescence anisotropy and were 
completed on a Photon Technologies
Inc. model QM-7/2003 SE fluorometer 
with polarization filters.  All anisotropy 
experiments consisted of purified GST-
mDia2 (47-396) protein (DID) 
sequentially added to a 10nM solution of 
wild-type DAD peptide, diluted in TMN 
buffer, pH 7.5.  The fraction of DAD 
peptide bound was determined by 
defining the largest anisotropy change as 
100% bound and comparing all other 
anisotropy data to that value.  The 
concentration of free DID was also 
determined by subtracting the total 
concentration of bound DID (calculated 
from the fraction bound) from the total 
concentration of DID.  The fraction 
bound data versus the concentration of 
free DID protein was plotted and fitted 
using GraphPad Prism (see Figure 4).
Results
R230, Q322 and I276 are Important to 
DID-DAD Binding – While it is known 
that the DID and DAD domains bind to 
each other in order to autoregulate the 
nucleation of actin, the contribution of 
all of the specific amino acid residues is 
not fully understood.  An important step 
in our project was to first prove that 
these residues are indeed important in 
DID-DAD binding.  By determining 
this, we are able to give further evidence 
that the binding of compounds I or II to 
these residues will result in alleviation of 
the DID-DAD interaction.  Binding 
curves generated from data obtained 
from fluorescence anisotropy have 
shown that the mutations R230L and 
Q322L resulted in lower binding affinity 
between DID and DAD, with 
dissociation constants (KD) of 2406 nM 
and 1380 nM, respectively, compared to 
a KD of 285.9 nM for wild type DID. 
The mutation I276D resulted in a KD 
greater than 20 μM (20,000 nM), which 
suggests complete lack of binding. 
From these data, we now know that 
these three residues (R230, Q322 and 
I276) are important to DID-DAD 
binding and are likely to bind to the 
compounds I/II.  As a result, an active 
state of the DRF and eventual cell death 
will result if these residues are unable to 
bind to DAD as a result of mutation or 
binding to a different compound.
Discussion
Discovering compounds that are able to 
bind to and affect the regulation of DRFs 
represents a novel advancement in 
modern chemotherapeutic drugs.  While 
current drugs that bind directly to the 
cytoskeleton are effective, they do 
exhibit side effects and eventual tumor 
cell resistance.  Creating a new drug that 
attacks the cell in an entirely different 
way will allow us to overcome these 
obstacles and possibly create an even 
more effective treatment.  Furthermore, 
determining the mechanism for these 
compounds binding to DRFs will allow 
us design compounds that are even more 
potent in the future
By using fluorescence 
anisotropy, we will soon be able to 
determine whether or not compounds I/II 
are able to displace DAD from DID. 
These experiments will involve titrating 
DID into DAD to a point just before 
saturation, and then adding either 
compound I or II sequentially to observe 
the results.  When normal binding 
occurs, anisotropy should increase, but 
the addition of these compounds should 
result in a decrease in anisotropy as a 
result of DAD peptide becoming free in 
solution and gaining the ability to rotate 
freely.  Anisotropy is a measure of the 
loss of motion, therefore freely rotating 
DAD peptide should result in a decrease 
in anisotropy because of an increase in 
motion.
Assuming these anisotropy 
experiments are successful, we will then 
move onto using isothermal titration 
calorimetry (ITC) (use of this machine 
provided to us by Dr. Nick Duesberry of 
the Van Andel Research Institute) to 
analyze direct binding between DID and 
compounds I/II.  Because we are unable 
to attach a fluorophore to either of these 
compounds, fluorescence anisotropy is 
unable to monitor this direct binding to 
DID and determine binding constants for 
each.  Knowing these binding constants 
will enable us to measure the strength of 
these interactions, and allow us to 
compare these values to future 
compounds that we may study.  The 
higher the affinity (stronger binding), the 
more potent and effective these 
compounds will be.  
While much advancement in the 
knowledge of DRFs (specifically mDia1 
and mDia2) has been made recently, 
much is still not known.  This project 
has enabled us to further determine 
specific residues important to DID-DAD 
binding in mDia2, helping to better 
understand the mechanism of their 
autoregulation.  Their naturally 
occurring autoregulatory mechanism is 
somewhat understood, but no synthetic 
chemical compound has been shown to 
artificially regulate these proteins.  If we 
are able to prove that the cell death 
experienced with the addition of these 
compounds is due to their binding to the 
DID region of DRFs, as well as 
determine the mechanism of this 
binding, we hope to use this information 
to eventually construct new compounds 
that will strongly bind to DID, thus 
creating a more potent anti-cancer drug.
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Figure 1.  Domain structure of a Diaphanous-related forming (mDia2).  DRFs consist 
of multiple domains that each contribute to the activity and regulation of these proteins. 
The known domains include G or GBD (GTPase-binding domain), FH1 (Formin 
homology 1 domain), DD (Dimerization domain), DID (Diaphanous inhibitory domain), 
FH2 (Formin homology 2 domain), CC (Coiled coil region), and DAD (Diaphanous 
autoregulatory domain).
Figure 2. Autoregulation of the Diaphanous-related formins.  (A) Naturally occurring 
mechanisms exist to regulate the activation of DRFs, such as the binding of Rho-GTPases 
to the GBD, disrupting the DID/DAD binding and activating the DRF and leading to cell 
movement and cell division.  (B) We have proposed that compounds I/II work much in 
the same manner, binding to the DID, but eventually causing cell death through 
prolonged activation.
(A)
Compound I Compound II
(B)
Figure 3.  Structure of compounds I/II.  (A) After a 10,000 compound scan, these 
two compounds were hypothesized to bind to mDia2 and in turn alleviate DID/DAD 
binding, thus activating this protein.  (B) Three residues:  arginine-230 (R230), 
glutamine-322 (Q322), and isoleucine-276 (I276) were then hypothesized to 
contribute to DID-Compound binding.  Based on a known structure of mDia1 (7), this 
is a proposed model of our protein interacting with Compound II.  There is no known 
structure of this complex.
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Figure 4.  Fluorescence anisotropy of the DID-DAD interaction.  The above curves 
were generated by the titration of wild type or mutant DID protein to fluorescent DAD 
peptide.  The mutant I276D has been left off of these curves because no significant 
binding was detected with this mutant.  (A) Raw data were generated for fluorescence 
anisotropy and plotted using GraphPad Prism.  Anisotropy change was determined by 
subtracting the initial anisotropy from the value obtained at each titration of DID.  As can 
be seen, anisotropy grows in magnitude with increasing concentrations of DID, indicating 
DID-DAD binding is occurring.  (B) Anisotropy binding curves were generated by 
obtaining the fraction of DAD peptide bound to DID and plotting that versus the free 
DID concentration using GraphPad Prism.
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